Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

ClinicalTrials.gov ID

NCT07584954

Lead Sponsor

Jun ZhouINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

90Estimated

Last Update Posted

May 13, 2026Actual

Start Date

Jun 18, 2024Actual

Primary Completion Date

Jun 30, 2028Estimated

Completion Date

Jun 30, 2028Estimated

Official Title

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

Brief Summary

This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor

Detailed Description

PD-L1 is universally expressed in various types of tumors and an important immune down-regulation factor in tumor microenvironment. Application of PD-L1 to cancer therapy is based on the inhibitory mechanism of the PD-L1/PD-1 pathway on T cell function, and as a result, PD-L1 blocking antibodies are developed, IUAb190708 is a humanized monoclonal immunoglobulin G1 κ subclass (IgG1) antibody that specifically recognizes PD-L1 (also known as CD274). Different from known PD-L1 blocking antibodies, i.e., they block the interaction of PD-L1 with PD-1 that recovers T cell function leading to indirect killing of tumor. Whereas IUAb190708 is to induce antibody dependent cell-mediated cytotoxicity (ADCC), i.e., it activates NK cells leading to direct killing of tumor.

IUAB190708 can be used as a monotherapy or in combination with other immunotherapies, chemotherapy, and radiation to improve the efficacy of tumor treatment.

In the open-label Phase I study, safety, tolerance, pharmacokinetics and activity of IUAb190708 in subjects with advanced or recurrent solid tumors will be evaluated, and MTD, DLT, and RP2D of IUAb190708 will be determined, and eligible subjects will be administered with IUAb190708 at different doses via intravenous infusion.

• Solid Tumor Cancer
• Solid Tumor Cancer Treatment With Immunotherapy

• IUAb190708, a cytotoxic antibody

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Male or female adult, age 18 - 75, understanding and voluntarily signing an informed consent form
2. A histologically confirmed diagnosis of Metastatic or locally advanced solid tumors, ineffective management of therapeutic regimen or currently no approved treatment available for the tumor, or unsuitable or refusing to receive standard treatment
3. In Phase Ia, for tumors with approved indications of anti PD-1/PD-L1 treatment, unrestricted to PD-L1 expression; for tumors that have not yet been approved for indications, positive expression of PD-L1 required. In Phase Ib, positive expression of PD-L1 is required
4. Subjects should provide fresh or archived tissue samples
5. Subjects must have at least one measurable lesion per iRECIST
6. Life expectancy ≥ 3 months
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
8. Adequate organ function, and no blood transfusion, erythropoietin (EPO), and granulocyte colony-stimulating factor at least 14 days before the study drug administration
9. All the female of child-bearing age must have a negative pregnancy test (unine or serum) during screening period and agree to use effective medical contraception from written informed consent to at least 6 months after the last administration of the study drug. Male partners also must agree to use effective medical contraception from written informed consent to at least 6 months after the last administration of the study drug.

Exclusion Criteria:

1. Serious/active infection or infection requiring intravenous antibiotic treatment within 4 weeks prior to the first dose of the study drug
2. Receiving nitrosourea and mitomycin C within 6 weeks prior to the first dose of the study drug; receiving oral fluorouracil derivatives or small molecule targeted drugs within 2 weeks prior to the first dose or 5 half-lives of the drug (whichever is longer); receiving endocrine therapy, Immunotherapy, or Traditional Chinese Medicine for anti-tumor indications within 2 weeks prior to the first dose of the study drug; receiving other anti-tumor therapies, such as chemotherapy, radiation, biotherapy, besides as described above treatments, within 4 weeks prior to the first dose of the study drug
3. Having other primary active malignant tumors within 5 years prior to the first dose of the study drug
4. Having clinically significant cardiovascular diseases,
5. Primary tumors of central nervous system or CNS metastatic tumors that have failed local treatment. For asymptomatic or clinically stable symptoms without the need for steroid hormones and other treatments for CNS metastasis lasting ≥ 28 days, CNS tumors under stable condition, including new CNS metastasis without any syndrome, confirmed by imaging during screening period can be enrolled.
6. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
7. History of allogeneic organ transplant.
8. Known history of infection with Human Immunodeficiency Virus (HIV) or other acquired or congenital immunodeficiency.
9. Patients with serious psychiatric or medical condition that could interfere with medication adherence.
10. Receiving systemic corticosteroid therapy (prednisone >10 mg/day or Bioequivalent dose of hydrocortisone) within 2 week prior to the first dose of trial treatment or receiving any other form of systemic immunosuppressive medication, except the condition as described below: treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids, or short-term (≤7 days) use of glucocorticoids for prophylactic treatment.
11. Active or history of autoimmune disease that requires systemic treatment within 2 years prior to enrollment (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). But the subjects with the following diseases are allowed to be enrolled: Type I diabetes with stable condition after using fixed dose insulin; Autoimmune hypothyroidism that only requires hormone replacement therapy.
12. History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, interstitial pneumonia or evidence of active pneumonia detected during chest CT scan screening.
13. Having experienced immune related adverse events of ≥ 3 grade during receiving any immunotherapy medication in the past.
14. Adverse reactions from previous anti-tumor treatments have not yet recovered to ≤1 grade per CTCAE 5.0 (except alopecia and other adverse reactions that the investigator determines that there is no safety risk)
15. Underwent major surgery within 4 weeks prior to the first dose of the study drug, or not fully recovered after surgery, or planned surgery within the expected participation time of the subject in the study or within 4 weeks after the last dose of the study drug.
16. Treponema pallidum antibody positive; active hepatitis B (HBsAg positive with HBV-DNA>500IU/mL); active hepatitis C (except subjects with HCV antibody positive and HCV-RNA <lower limit of clinical research organization).
17. Subjects with history or current evidence of any clinical condition or laboratory abnormality or other reasons are not suitable to participate in this clinical study by the investigator.
18. Female who are pregnant or breastfeeding
19. Subjects with history of other serious systemic diseases are not suitable to participate in this clinical study by the investigator.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Jun ZhouINDUSTRY

Collaborators

Fudan UniversityOTHER

Hunan Cancer HospitalOTHER

Fujian Cancer HospitalOTHER_GOV

Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER

Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER

Shandong Cancer Hospital and InstituteOTHER

Anyang Tumor HospitalOTHER

ayhmghw@163.com(+86)0372-2233010

enyingcao@yeah.net(+86)15902114065

shfkgcp@163.com(+86)021-65115006 ext. 1053

Joanshenwei@126.com（+86）13301788863

• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

  NCT05856981

  RecruitingInterventionalPhase 1Updated Dec 17, 2025
• Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

  NCT05508100

  CompletedInterventionalPhase 1Updated May 24, 2024
• A Study of MSB2311 in Advanced Solid Tumors

  NCT04272944

  CompletedInterventionalPhase 1Updated Dec 18, 2023
• A Study of the ILB-3101 in Patients with Advanced Solid Tumors

  NCT06426680

  RecruitingInterventionalPhase 1Updated Dec 9, 2024
• A Study of LY3435151 in Participants With Solid Tumors

  NCT04099277

  TerminatedInterventionalPhase 1Updated Aug 31, 2021
• A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

  NCT07172802

  RecruitingInterventionalPhase 1Phase 2Updated Sep 15, 2025